36.64 +0.04 (0.11%)
After hours: 4:14PM EST
|Bid||36.60 x 100|
|Ask||36.69 x 100|
|Day's range||36.47 - 36.98|
|52-week range||30.90 - 37.35|
|PE ratio (TTM)||22.61|
|Earnings date||30 Jan 2018|
|Forward dividend & yield||1.36 (3.72%)|
|1y target est||38.38|
Jan.10 -- Nestle is emerging as the lead bidder to acquire Merck's consumer health business for as much as $5 billion. Ruth David reports on "Bloomberg Markets."
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.
There's talk that tax reform could give biotech M&A a kick-start. If it does, then investors will want to keep tabs on these stocks.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.
Merck's (MRK) Keytruda rapidly grows as its key top-line driver. The Keytruda development program shows significant advancement in 2017.
Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.
Donald Trump says his corporate tax cuts are setting off a domino effect that will finally end the long, lean years for American wage-earners.
Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.
With the U.S.'s new tax law coming into effect, many companies will see a significant impact from changes in their effective tax rates (some more than others). In this note, we focus on some of the major pharmaceutical firms such as Pfizer, Johnson & Johnson, Merck and Bristol-Myers Squibb.
On December 14, 2017, Teva (TEVA) stock gained more than 10% on the back of the announcement of a comprehensive restructuring plan and additional measures to improve the company’s operational and financial performance. On December 14, 2017, the Generic Drugs ETF (GNRX) rose by approximately 1.0%. Teva Pharmaceuticals has a debt of $32 billion, which needs to be serviced in an organized manner to strengthen the company’s financials and bring down leverage.
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.
When Miles White was named CEO of Abbott Laboratories, he was the youngest head of a major health care company. Now he's one of the longest serving.
Teva Pharmaceuticals released its 3Q17 earnings results on November 2, 2017. The disappointing earnings and the company’s lowering of its fiscal 2017 guidance triggered negative investor sentiments, which led to a massive decline of approximately 20% in TEVA stock prices. The company has run into troubles over the past year and it reported a dismal performance in 3Q17. For details, read, Inside Teva’s 3Q17 Performance.
The company will be launching its Phase 3 TAHOE study to compare Rova-T with topotecan, the only therapy in second line SCLC approved by the FDA (U.S. Food & Drug Administration). AbbVie also aims to establish the importance of targeting tumor-initiating cells in treating solid tumors. Beyond 2020, the company plans to launch the MERU study, which will enable Rova-T to expand its label in the first line SCLC maintenance indication.